PHCentral RSS - rss FIRE feed Mon, 22 Dec 2014 19:12:22 GMT Happy Holidays to All! December 20, 2014 First results of Russia's national PH registry December 19, 2014 Cytori Announces Informational Session on Potential Therapy for Scleroderma December 19, 2014 The ocular impact of Sildenafil December 19, 2014 click headline for more

Interleukin 13– and interleukin 17A–induced pulmonary hypertension phenotype due to inhalation of antigen and fine particles from air pollution December 18, 2014

A bunch of exciting free fulltext PH-aticles from PVRI December 17, 2014 The first annual Drug Discovery and Development Symposium for Pulmonary Hypertension December 17, 2014 [..]
A "must read" article for interested PH patients, click headline
Acute hemodynamic response of infused fasudil in patients with pulmonary arterial hypertension: A randomized, controlled, crossover study. December 17, 2014 GlaxoSmithKline seeks expanded hypertension approval for Volibris December 16, 2014 The Year in Medicine 2014: News That Made a Difference December 16, 2014 A predictive model of the effects of depression, anxiety, stress, 6-minute-walk distance, and social support on health-related quality of life in an adult pulmonary hypertension population. December 16, 2014 GSK Seeks European Approval for Ambrisentan as PAH Combination Therapy December 15, 2014 Silence Therapeutics To Utilize New Genetic Toolkit For PAH Drug Development December 13, 2014 FDA Postmarket Trial for PAH Treatment Bosentan Reveals Drug Does Not Reduce Time To Mortality Rates December 12, 2014 Actelion European MAA for PAH Drug Selexipag Pending Approval December 11, 2014 ...
According to a report published June 2014, Selexipag reduced the risk of morbidity/mortality in PAH patients by 39 percent, compared to those who received a placebo. Treatment response was consistent across patient subgroups (age, gender, WHO Functional Class, PAH etiology and background PAH therapy) treated for up to 4.2 years.]]>
STAT5a/b Gene May Be Responsible for Gender Differences in Pulmonary Hypertension December 10, 2014 ...
The STAT a/b gene may control the severity of pulmonary hypertension and could be controlled by estrogen levels. This could explain why women do not get as severe pulmonary hypertension as men.
New Clinical Trial Tests Ambrisentan in Preventing SSc-PAH December 9, 2014 Researchers Uncover New Insights Into Vascular Receptor Autoantibodies in PAH Associated with SSc December 8, 2014 Noninvasive PAH diagnosis on the horizon December 7, 2014 New Clinical Trial Tests Ambrisentan in Preventing SSc-PAH December 7, 2014 Eight Parameters Recommended to Monitor for PH in JSSc Patients December 7, 2014 The Flavonoid Quercetin Reverses Pulmonary Hypertension in Rats December 6, 2014 Researchers Discover Protein That Can Prevent Pulmonary Hypertension-Related Heart Failure December 6, 2014 Plos One.]]> Prevalence, Determinants, and Prognostic Significance of Pulmonary Hypertension in Elderly Patients Admitted with Acute Decompensated Heart Failure: A Report from the BIO-HF Registry. December 5, 2014 Gene assosiated with gender differences in experimental PAH in mice fould December 4, 2014 CYP2C9 gene associated with bosentan-induced liver injury{002b864e-6713-449b-be1f-f6d3625aaae8}/cyp2c9-gene-associated-with-bosentan-induced-liver-injury December 3, 2014 Ellagic acid prevents monocrotaline-induced pulmonary artery hypertension via inhibiting NLRP3 inflammasome activation in rats. December 3, 2014 PH Diagnosis, Treatment Aided By New Right Ventricle 4D RV-Function Imaging Systems December 2, 2014 ACTELION SUBMITS SELEXIPAG (UPTRAVI) FOR EMA MARKETING AUTHORISATION IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION December 1, 2014 ACTELION SUBMITS SELEXIPAG (UPTRAVI) FOR EMA MARKETING AUTHORISATION IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION December 1, 2014 Identification of treatment goals in paediatric pulmonary arterial hypertension December 1, 2014
From the identified set of baseline predictors, the variables World Health Organization functional class (WHO-FC), N-terminal pro-brain natriuretic peptide (NT-proBNP) and tricuspid annular plane systolic excursion (TAPSE) were identified as follow-up predictors in which treatment-induced changes were associated with survival. Patients in whom these variables improved after treatment showed better survival (p<0.002).

Therefore, WHO-FC, NT-proBNP and TAPSE are not only predictors of transplant-free survival in paediatric PAH but can also be used as treatment goals, as treatment-induced improvements in these variables are associated with improved survival. The identification of these variables allows for the introduction of goal-oriented treatment strategies in paediatric PAH.]]>
Patients With Reactive Pulmonary Hypertension Present Higher Mortality Risk November 30, 2014 Boehringer Ingelheim’s Nintedanib for IPF Receives Positive Opinion November 30, 2014 Proteomics of pulmonary hypertension: could personalized profiles lead to personalized medicine? November 30, 2014 Surgical Cure for CTEPH Available in Vanderbilt Medical Center November 29, 2014 Pentraxin3 in Chronic Thromboembolic Pulmonary Hypertension: A New Biomarker for Screening from Remitted Pulmonary Thromboembolism November 29, 2014 miR-29a-3p Attenuates Hypoxic Pulmonary Hypertension by Inhibiting Pulmonary Adventitial Fibroblast Activation;HYPERTENSIONAHA.114.04600v1 November 29, 2014 Why drying washing indoors can pose a serious health threat November 28, 2014 Arena Pharma granted patent for pulmonary hypertension drug November 27, 2014 SSc-PAH Patients Demonstrate Endothelial-to-Mesenchymal Transition November 26, 2014 Researchers Report Thymosin Beta 4 is Cardioprotective in Pulmonary Hypertension/Heart Failure Model November 25, 2014 Long-term Benefit With Stem-Cell Transplant in Scleroderma November 24, 2014 New Pulmonary Fibrosis Diagnostic Tool Would Be Faster & Quicker November 23, 2014 Lung Transplantation Decisions For Scleroderma Patients Should Be Rethought, Study Says November 23, 2014